NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2023 (fiscal 2023 third quarter), filed May 15, 2023. This differs from the request metadata’s “2022 Q3.” The interim financial statements are unaudited.
Business context
NanoViricides is a clinical-stage antiviral drug developer with no commercialized products or revenue. Its lead candidate, NV-CoV-2, contains NV-387 and is being developed for COVID-19. Other programs include NV-CoV-2-R, a shingles candidate, and exploratory programs targeting mpox, RSV and other viruses. The company relies on exclusive technology licenses from related party TheraCour Pharma.
Financial performance and position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | None | None |
| Research and development | 2023: $1.196 million; 2022: $1.255 million | 2023: $3.479 million; 2022: $4.613 million |
| General and administrative | 2023: $615,000; 2022: $533,000 | 2023: $1.788 million; 2022: $1.708 million |
| Net loss | 2023: $1.703 million ($0.15/share); 2022: $1.793 million ($0.16/share) | 2023: $5.019 million ($0.43/share); 2022: $6.327 million ($0.55/share) |
- Cash and cash equivalents: $9.651 million at March 31, 2023, down from $14.066 million at June 30, 2022.
- Cash flow: Operating activities used $4.171 million in the nine months, versus $4.494 million in the comparable 2022 period. Investing activities used $149,000, primarily for property and equipment; financing activities used $95,000 to repay a loan.
- Liquidity and debt: Current assets were $9.931 million and current liabilities $349,000. The insurance-financing loan balance was zero, versus $95,000 at June 30, 2022. Total assets were $18.577 million; stockholders’ equity was $18.228 million.
- Accumulated deficit: $127.511 million. No income tax provision was recorded due to ongoing losses. Gross margin is not applicable because the company had no revenue.
Material changes versus the prior comparable period
- Nine-month net loss narrowed by about $1.308 million, mainly as R&D expense fell by $1.134 million. The prior-year period included a $935,000 related-party license milestone expense; the company also cited lower external laboratory costs.
- Quarterly net loss improved by about $90,000. Quarterly R&D declined, partly offset by higher general and administrative expense, attributed to professional fees.
- Interest income rose to $249,000 for the nine months from zero, reflecting higher interest rates; interest expense declined as the company did not finance its 2023 directors’ and officers’ insurance.
- Cash decreased by $4.415 million from June 30, 2022. Common shares outstanding increased from 11.592 million to 11.666 million.
Outlook, commentary and risks
- Management said existing resources were expected to fund planned operations for at least 12 months from the filing date. It expects continuing losses and says additional capital will be needed for longer-term operations and later-stage trials. Future funding may include grants, licensing or partnerships, and equity financing; there is no assurance funding will be available on favorable terms.
- At filing, Phase 1a/1b trials of NV-CoV-2 oral formulations in India were awaiting notice of trial commencement. Karveer had obtained Indian regulatory permission, and the company reported the trial drug shipment was received in India in April 2023. The company is responsible for reimbursing trial costs plus a 30% management fee. Karveer is a related party through CEO and Chairman Anil Diwan’s passive investment and board role.
- The March 2023 Karveer agreement provides for a 70% royalty to NanoViricides on qualifying sales to unaffiliated third parties. The company said it would receive trial reports and could use the data for regulatory development outside India.
- The injectable COVID trial program was put on hold while the company focused on manufacturing oral trial supplies. Further clinical development depends on trial outcomes, regulatory requirements, partners and funding. Management’s statements about efficacy, safety, broad antiviral potential and future milestones are forward-looking; the lead candidate had not yet entered human trials as of the filing.
- The business depends on TheraCour’s licensed technology and development services. Related-party R&D costs were $1.868 million for the nine months; amounts payable to TheraCour, net of a $465,000 advance, were $244,000 at period-end. Loss of the licenses could delay development and increase costs.
- Disclosure controls were deemed ineffective as of March 31, 2023 because of a previously identified material weakness involving timely and effective review of the period-end close and adequate personnel and resources. Management described a remediation committee and review process.
- The company reported no pending legal proceedings known to it and no off-balance-sheet arrangements during the nine-month period.
Important facts for investors to verify
- Whether the India Phase 1a/1b trial began, its enrollment and protocol, and when results will be available.
- Actual clinical-trial costs, the timing and funding of later trials, and whether the company raises capital or secures a development partner.
- Whether reported cash runway assumptions remain valid as clinical and manufacturing spending changes.
- Progress in remediating the material weakness and whether disclosure controls become effective.
- Terms, governance and economics of the related-party arrangements with TheraCour and Karveer, including trial reimbursement and potential royalties.
- Potential dilution from equity compensation, warrants and Series A preferred stock, which is convertible into common shares upon a change of control.